CN104587094A - Pharmaceutical composition for treating macular hemorrhage in high myopia and application of pharmaceutical composition - Google Patents
Pharmaceutical composition for treating macular hemorrhage in high myopia and application of pharmaceutical composition Download PDFInfo
- Publication number
- CN104587094A CN104587094A CN201510070345.9A CN201510070345A CN104587094A CN 104587094 A CN104587094 A CN 104587094A CN 201510070345 A CN201510070345 A CN 201510070345A CN 104587094 A CN104587094 A CN 104587094A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- hemorrhage
- high myopia
- fructus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the technical field of medicine, and in particular relates to a pharmaceutical composition for treating macular hemorrhage in high myopia and an application of the pharmaceutical composition. The pharmaceutical composition consists of the following components: ginseng, fruit of Chinese wolfberry, longan aril, raspberry, pollen typhae, pomegranate flower, coptis chinensis, cassia twig, colla corii asini, pseudo-ginseng, glossy privet fruit, semen plantaginis and Chinese starjasmine stem. The pharmaceutical composition disclosed by the invention is a pure traditional Chinese medicine pharmaceutical composition, is reasonable in formula and is applied according to syndrome differentiation, and the pharmaceutical composition has a relatively good curative effect on macular hemorrhage in high myopia, and in particular on macular hemorrhage in high myopia caused by deficiency fire and collateral injury.
Description
Technical field
The invention belongs to medical art, be specifically related to a kind of medical composition and its use for the treatment of macular hemorrhage in high myopia.
Background technology
Macular hemorrhage in high myopia belongs to the category such as TCM Ophthalmology " sudden blindness ", " chromatopsia ", " blurring of vission ", one of oculopathy of grievous injury central vision, it absorbs difficulty, and time length easily causes paralysed trace and pigment hypertrophy, so that causes permanent low visual acuity or blinding.High myopia also claims pathologic myopia, and because pathologic myopia Posterior pole retina is along with the prolongation of the course of disease, the lengthening of axis oculi, is damaged to macular area blood capillary, occurs that macula area is hemorrhage.Macular hemorrhage in high myopia, the associated with choroidal new vessels according to whether, is divided into simple type and neovascular 2 kinds, and the reason that pathological changes occurs mainly contains inherited genetic factors, Biomechanical factor, outside environmental elements etc.Clinically for the macular hemorrhage in high myopia Therapeutic Method adopting inert gas injecting, laser therapy and relevant Western medicine symptomatic treatment in operation or vitreous chamber more, but operation method can cause related complication, and be not suitable for the punctum luteum hemorrhage of the less or comparatively fresh of amount of bleeding; Laser can only prevent hemorrhage generation again, cuts little ice for hemorrhage absorption, and the curative effect of Western medicine still has to be seen.
The traditional Chinese medical science thinks that the dirty in liver,spleen,kidney three of primary disease duty, liver blood kidney essense consume wound and can not support order and cause blurring of vision visual deterioration; Stagnation of liver-QI with deficiency of the spleen, seminal fluid is not transported, and gathers for phlegm-damp, and blood does not support arteries and veins then new vessels formation; Liver is insufficiency of the spleen can not have blood vessels under one's command, or asthenic fire hinders network, then hemorrhage outside blood oozing from the body openings or subcuta neous tissue network.According to clinical symptoms, pathogenic analysis and Coryza Treated by Syndrome Differentiation, can be divided into deficiency of the liver and kindey, asthenic fire hinders network, insufficiency of vital energy and blood three kinds of pattern of syndrome, and clinical to hinder network type with asthenic fire in the majority.In treatment, with tonic Liver and kidney essence and blood, clearind deficient heat, and blood vessels are main, the normal operation taking into account spleen is auxiliary, and determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs, obtains good therapeutic effect.
Summary of the invention
The invention provides a kind of new pharmaceutical composition for the treatment of macular hemorrhage in high myopia, overcome prior art deficiency, have good curative effect, and toxic and side effects is little.Described pharmaceutical composition is obtained by following raw material: Radix Ginseng, Fructus Lycii, Arillus Longan, Fructus Rubi, Pollen Typhae, Flos Granati, Rhizoma Coptidis, Ramulus Cinnamomi, Colla Corii Asini, Radix Notoginseng, Fructus Ligustri Lucidi.
Preferably, described pharmaceutical composition also comprises Semen Plantaginis and Caulis Trachelospermi.
The technical scheme adopted for solving its technical problem is the pharmaceutical composition of described treatment macular hemorrhage in high myopia, be made up of the medicine of following weight: Radix Ginseng 6-8 part, Fructus Lycii 10-12 part, Arillus Longan 10-12 part, Fructus Rubi 8-11 part, Pollen Typhae 6-8 part, Flos Granati 10-12 part, Rhizoma Coptidis 6-8 part, Ramulus Cinnamomi 7-9 part, Colla Corii Asini 5-7 part, Radix Notoginseng 8-12 part, Fructus Ligustri Lucidi 10-12 part.
Preferably, described pharmaceutical composition also comprises the medicine of following weight: Semen Plantaginis 8-10 part and Caulis Trachelospermi 8-12 part.
Most preferred technique scheme of the present invention is, described pharmaceutical composition of the present invention, is obtained by the raw material of following weight portion: Radix Ginseng 7 parts, Fructus Lycii 11 parts, Arillus Longan 11 parts, Fructus Rubi 9 parts, Pollen Typhae 7 parts, Flos Granati 11 parts, Rhizoma Coptidis 7 parts, Ramulus Cinnamomi 8 parts, 6 parts, Colla Corii Asini, Radix Notoginseng 10 parts, Fructus Ligustri Lucidi 11 parts, Semen Plantaginis 9 parts, Caulis Trachelospermi 10 parts.
Present invention also offers the preparation method of described pharmaceutical composition, after specifically comprising the steps: the raw material of above-mentioned weight portion to pulverize respectively, soak 4 hours, decoct 2 times, each 60 minutes, filter, merging filtrate, and filtrate when being concentrated into 75 DEG C relative density be 1.16-1.18, room temperature to be chilled to, adds ethanol and makes alcohol content reach 75%, leave standstill 12 hours, leaching supernatant, reclaims ethanol, and when being concentrated into 75 DEG C, relative density is the Chinese medical concrete of 1.12-1.15.
Those skilled in the art directly can be used as medicine on obtained active constituents of medicine basis of the present invention to use or add on pharmaceutics acceptable adjuvant routinely technique be prepared into required preparation.Preferably, pharmaceutical composition of the present invention conveniently preparation technology be prepared into tablet or capsule.Described capsule is after being pulverized by active component and adjuvant sodium alginate, MgCO
3, stearic acid crosses 80 mesh sieves, mix homogeneously, granulate with dry granulating machine, 20 mesh sieves carry out granulate, particles filledly in hard capsules, namely obtain this product by obtained.
The present invention also asks to protect aforementioned pharmaceutical compositions especially to hinder purposes in network type macular hemorrhage in high myopia medicine in preparation treatment asthenic fire in preparation treatment macular hemorrhage in high myopia.In clinical observation process, treatment group 30 example 35 eyes, matched group 30 example 33 eyes, two groups of there was no significant differences (P > 0.05) in sex, age, the course of disease etc., have comparability.After surrounding treatment, all complete clinical observation, efficacy result treatment group total effective rate is 94.3%, and matched group total effective rate is 81.8%, two kinds of Therapeutic Method have significant difference (P < 0.05), and treatment group curative effect is better than matched group.In therapeutic process, vital sign patient steadily and without serious adverse reactions such as allergy, show that the clinical application of we is safely and effectively, is worth studying and applying further.
Further, pharmaceutical composition of the present invention, described Radix Ginseng, sweet micro-hardship, temperature.Enter spleen, lung meridian.Strongly invigorating primordial QI, promotes the production of body fluid Gu de-, calms the nerves.Control impairment caused by overstrain deficient, lack of appetite, asthenia, food is told in regurgitation, stool lingering diarrhea, and empty cough with asthma is urged, spontaneous perspiration sudden collapse, palpitation with fear, forgetful, dizziness and headache, sexual impotence, and frequent micturition, quenches one's thirst, woman uterine bleeding, children's's intermittent infantile convulsion, and prolonged deficiency is not multiple, the card of all qi-blood-body fluid deficiencies.
Fructus Lycii, sweet, flat.Return liver, kidney channel.Nourishing the liver and kidney, replenishing vital essence to improve eyesight.For asthenia damage of essence, soreness of waist and knee joint, vertigo and tinnitus, interior-heat is quenched one's thirst, blood deficiency and yellow complexion, and blurred vision is failed to understand.
Arillus Longan, sweet, temperature.GUIXIN, spleen channel.Invigorating the heart and spleen, nourishing blood to tranquillize the mind.For insufficiency of vital energy and blood, severe palpitation, forgetful insomnia, blood deficiency and yellow complexion.
Fructus Rubi, sweet acid; Flat; Nontoxic.Liver; Kidney channel.The liver and the kidney tonifying, controlling nocturnal emission with astringent drugs reducing urination, improving eyesight.Main impotence and premature ejaculation, emission and spermatorrhea, cold womb is infertile, and leukorrhagia is rare clearly, frequent micturition incontinence of urine, and blurred vision is dark, early whitening of beard and hair.
Pollen Typhae, Gan Xin is cool.Enter liver, heart channel.Cooling blood for hemostasis, activating blood circulation and dissipating blood stasis.Raw with controlling amenorrhea stomachache, postpartum stagnation is had a pain, and falls that to flutter blood vexed, furuncle toxic swelling; Fry black emesis blood, epistaxis, metrorrhagia, rushes down blood, hematuria, dysentery, leukorrhagia; External treatment congenital deformity of the tongue, aphtha, Ting discharging ear, hemorrhage in ear, uncontrolled urination is itched.
Flos Granati, sour in the mouth; Puckery; Property is put down; Removing heat from blood; Hemostasis.Main epistaxis; Spit blood; Traumatic hemorrhage; Menoxenia; Redly collapse leucorrhea; Otitis media.
Rhizoma Coptidis, bitter; Cold.The heart; Liver; Stomach; Large intestine channel.Clearing away heat-fire; Dampness; Removing toxic substances.Main calentura heresy enters the high heat of heart channel; Irritated; Delirium or the absurd row of intenseness of heat forcing blood tell nosebleed; Damp and hot breast painful abdominal mass; Have loose bowels; Dysentery; The vexed insomnia of hyperactivity of heart-fire; Gastropyretic vomiting or rapid digestion of food and polyorexia; Liver-fire conjunctival congestion and swelling pain; And pathopyretic ulcer; Furunculosis septicemia; Gingival swelling and pain; Aphtha of the mouth and tongue; Ting ear; Swelling of the vulva; Hemorrhoidal bleeding; Eczema; Scald.
Ramulus Cinnamomi, pungent; Sweet; Warm in nature.Bladder; The heart; Lung meridian.Expelling cold and relieving exterior syndrome; Promoting the flow of QI-blood by warming the meridian; Activating YANG and prormoting functioning of QI.Main exterior syndrome due to wind-cold; Arthralgia due to cold-dampnes; Extreme cold of the limbs; Amenorrhea dysmenorrhea; Lump in the abdomen lumps; The thoracic obstruction; Cardiopalmus; Phlegm retention; Dysuria.
Colla Corii Asini, sweet, flat.Return lung, liver, kidney channel.To enrich blood YIN nourishing, moisturize, hemostasis.For blood deficiency and yellow complexion, dizzy cardiopalmus, flesh flaccidity is unable, dysphoria and insomnia, stirring-up of pathogenic wind in the interior resulting from deficiency, xeropulmonary cough, and chronic cough is spat blood, haematemesis hematuria, metrorrhagia of having blood in stool, vaginal bleeding during pregnancy.
Radix Notoginseng, sweet, micro-hardship, temperature.Return liver, stomach warp.Dissipating blood stasis stops blooding, subduing swelling and relieving pain.For spitting of blood, spit blood, epistaxis, has blood in stool, metrorrhagia, traumatic hemorrhage, and breast abdomen twinges, tumbling and swelling.
Fructus Ligustri Lucidi, sweet, bitter, cold.Return liver, kidney channel.Nourishing the liver and kidney, improving eyesight black hair.For vertigo and tinnitus, soreness of the waist and knees, early whitening of beard and hair, poor vision.
Semen Plantaginis, sweet, be slightly cold.Return liver, kidney, lung, small intestine meridian.Clearing away heat and promoting diuresis, eliminating dampness by diuresis is treating stranguria, improving eyesight, eliminates the phlegm.For edema distension, the puckery pain of pyretic stranguria, diarrhea due to summer heat and dampness, conjunctival congestion and swelling pain, phlegm-heat cough.
Caulis Trachelospermi, bitter, cool, enter liver, kidney channel.Dispel the wind, dredging collateral, hemostasis, repercussive.Dispelling the wind and dampness pathogens arthralgia pain, the contracture of muscle arteries and veins, carbuncle, sore throat, spits blood, traumatic injury, disease that postpartum lochia can't go.
Above-mentioned all medicines share, benefiting kidney-essence, clearing away heat and cooling blood, and take into account the normal operation of spleen, giving consideration to both the incidental and fundamental, QI and blood is ruled together, and especially hinder network type macular hemorrhage in high myopia to asthenic fire have clear improvement to macular hemorrhage in high myopia.Through clinical practice checking, its determined curative effect, mild in medicine property and, do not occur toxic and side effects and untoward reaction, safety coefficient is high, clinical observation total effective rate nearly 95%.
Detailed description of the invention
Further describe the present invention below by way of specific embodiment, but the present invention is not limited only to following specific embodiment.Within the scope of the invention or not departing from content of the present invention, spirit and scope, the change carried out the present invention, combination or replacement, be apparent for a person skilled in the art, and be included within the scope of the present invention.
Embodiment 1
The each raw material of the present invention is taken: Radix Ginseng 7 parts, Fructus Lycii 11 parts, Arillus Longan 11 parts, Fructus Rubi 9 parts, Pollen Typhae 7 parts, Flos Granati 11 parts, Rhizoma Coptidis 7 parts, Ramulus Cinnamomi 8 parts, 6 parts, Colla Corii Asini, Radix Notoginseng 10 parts, Fructus Ligustri Lucidi 11 parts, Semen Plantaginis 9 parts, Caulis Trachelospermi 10 parts by following weight portion.
Preparation technology is as follows:
After the raw material of above-mentioned weight portion is pulverized respectively, soak 4 hours, decoct 2 times, each 60 minutes, filter, merging filtrate, and filtrate is concentrated into relative density is 1.16-1.18 (75 DEG C of surveys), room temperature to be chilled to, adding ethanol makes alcohol content reach 75%, leaves standstill 12 hours, leaching supernatant, reclaim ethanol, when being concentrated into 75 DEG C, relative density is the Chinese medical concrete of 1.12-1.15.Those skilled in the art directly can be used as medicine and be used or add adjuvant sodium alginate, MgCO on this basis
3, stearic acid crosses 80 mesh sieves, mix homogeneously, granulate with dry granulating machine, 20 mesh sieves carry out granulate, particles filledly in hard capsules, namely obtain Traditional Chinese medicine preparation capsule agent of the present invention by obtained.
When using medicine composite for curing macular hemorrhage in high myopia disease of the present invention, take prepared capsule, every contains crude drug amount 0.4g, and every day 3 times, each 4-6 grain, takes after meal half an hour.
Embodiment 2
The each raw material of the present invention is taken: Radix Ginseng 6 parts, Fructus Lycii 10 parts, Arillus Longan 10 parts, Fructus Rubi 8 parts, Pollen Typhae 6 parts, Flos Granati 10 parts by following weight portion, Rhizoma Coptidis 6 parts, Ramulus Cinnamomi 7 parts, Medulla Tetrapanacis 10 parts, Herba Asari 8 parts, 5 parts, Colla Corii Asini, Radix Notoginseng 8 parts, Thallus Laminariae (Thallus Eckloniae) 10 parts, Fructus Ligustri Lucidi 10 parts, Semen Plantaginis 8 parts, Caulis Trachelospermi 8 parts.
Preparation technology is with embodiment 1.
Embodiment 3
The each raw material of the present invention is taken: Radix Ginseng 8 parts, Fructus Lycii 12 parts, Arillus Longan 12 parts, Fructus Rubi 11 parts, Pollen Typhae 8 parts, Flos Granati 12 parts, Rhizoma Coptidis 8 parts, Ramulus Cinnamomi 9 parts, 7 parts, Colla Corii Asini, Radix Notoginseng 12 parts, Fructus Ligustri Lucidi 12 parts, Semen Plantaginis 10 parts, Caulis Trachelospermi 12 parts by following weight portion.
Preparation technology is with embodiment 1.
Embodiment 4
The each raw material of the present invention is taken: Radix Ginseng 6 parts, Fructus Lycii 10 parts, Arillus Longan 12 parts, Fructus Rubi 11 parts, Pollen Typhae 6 parts, Flos Granati 10 parts, Rhizoma Coptidis 8 parts, Ramulus Cinnamomi 9 parts, 5 parts, Colla Corii Asini, Radix Notoginseng 8 parts, Fructus Ligustri Lucidi 12 parts, Semen Plantaginis 10 parts, Caulis Trachelospermi 12 parts by following weight portion.
Preparation technology is with embodiment 1.
Embodiment 5
The each raw material of the present invention is taken: Radix Ginseng 8 parts, Fructus Lycii 12 parts, Arillus Longan 10 parts, Fructus Rubi 8 parts, Pollen Typhae 8 parts, Flos Granati 12 parts, Rhizoma Coptidis 6 parts, Ramulus Cinnamomi 7 parts, 7 parts, Colla Corii Asini, Radix Notoginseng 12 parts, Fructus Ligustri Lucidi 10 parts, Semen Plantaginis 8 parts, Caulis Trachelospermi 8 parts by following weight portion.
Preparation technology is with embodiment 1.
The clinical observation of embodiment 6 medicine composite for curing macular hemorrhage in high myopia of the present invention
1, case-data: that selects hospital ward and outpatient clinic meets case totally 60 examples (68 eyes) that asthenic fire hinders network type macular hemorrhage in high myopia standard, wherein male 31 example, women 29 example.Age 34-75 year, average 53 years old.Disease time: the shortest 7 days, the longest 3 years, average 281 days.Axis oculi by 25.22mm-29.37mm, average 27.6mm.Suffer from refraction of eye situation :-6.46D-15.27D, average-7.8D.Fundus Oculi Manifestations: 68 visible optic disc atrophy arcs, 63 is leopard stricture of vagina shape optical fundus, and 56 have posterior scleral staphyloma, the large stretch of choroidal atrophy of 52 companions, and 21 Posterior pole are shown in paint crackle, 20 soon fuchs speckles.By random assortment block-regulations, patient is divided into treatment group and matched group randomly.Wherein treatment group 30 example 35 eyes, matched group 30 example 33 eyes, two groups of there was no significant differences (P > 0.05) in sex, age, the course of disease etc., have comparability.
2, diagnostic criteria: formulate according to " retinopathy " related content:
2.1 symptoms and sign:
2.1.1 visual deterioration, conscious metamorphopsia, visual deterioration or central scotoma;
2.1.2 visible punctum luteum hemorrhage district under ophthalmoscope, ovalize, similar round or irregular type, be confined to more central fovea or near, edge is still clear, the visible near-sighted arc of nethike embrane, the performance of the paint Myopia characteristic such as crackle or Fuchs speckle;
2.1.3 fluoroscopic visualization is the very thin new vessels forms such as patch shape, lacery, wheel shape, graininess, knitting wool bulk tremulous pulse early stage or arterial phase, and can occur fluorescence leakage after new vessels development, bleeding part choroid background fluorescence is blocked all the time.
2.2 diagnostic criteria
2.2.1 refraction of eye degree is more than or equal to-6.0D.
2.2.2 axis oculi is greater than 24mm.
2.2.3 macular area is shown in hemorrhage.
2.3 Syndrome Differentiation of Traditional Chinese Medicines:
Asthenic fire is hindered network type disease and is seen hemorrhage comparatively fresh, dysphoria with feverish sensation in the chest palms and soles, dryness of the mouth and throat, the few tongue of red tongue, thready and rapid pulse.
3, case standard is included in:
3.1 patients being diagnosed as macular hemorrhage in high myopia.
3.2 accept therapy of combining Chinese and Western medicine and follow up a case by regular visits to satisfied patient.
The comparatively complete person of 3.3 case-datas, auxiliary examination at least comprises fundus photography and fluorescence fundus angiography.
4, Excluded cases standard:
4.1 suffer from illness at the bottom of other serious oculars simultaneously, cannot determine it is the case which kind of cause influence suffers from eye visual function.
4.2 treatments period endogenous causes of ill suffer from more serious Medicine and Surgery disease and disturb the case of ophtalmic treatments.
4.3 cases accepting PDT, TTT, intraocular injection anti-VEGF (VEGF) medicine or operative treatment.
5, case standard is rejected:
(1) rear discovery is included in exclusion standard disease patient;
(2) case of medication is not specified by testing program;
(3) drug administration process data logging is incomplete, cannot judge curative effect person.
6, to come off and termination criteria:
(1) observe in patient exit voluntarily, person lost to follow-up;
(2) there is the person that should not continue reception test such as complication or special physiological change in experimenter;
(3) serious adverse reaction occurs person in test, should stop clinical trial in time.
Come off and answer itemized record reason with the case stopped, and the switching of its last curative effect testing result is added up for final result.
7, usage and dosage:
Treatment group: take medicine composite for curing of the present invention, capsule prepared by Example 1, every capsules containing crude drug amount 0.4g, every day 3 times, each 5, after meal half an hour warm water delivery service.
Matched group: take Wo Liting (lecithin chelated iodine sheet, 1.5mg × 60 slice/box, H20020205), every day three times, each 3, be used in conjunction surrounding.
Check that patient corrects rear vision, retinal hemorrhage absorbing state and underwent eye-ground vascular fluorescence visualization situation respectively at after medication two weeks and surrounding by special messenger.
8, curative effect determinate standard:
Be curative effect determinate standard according to " national traditional Chinese medical science industry standard-Chinese medical disease Standardization of diagnosis and curative effect ".Cure: correct defects of vision before vision restoration to disease, macula area is hemorrhage to be absorbed completely, fluoroscopic visualization display new vessels is visible, and choroid fluorescence blocked area disappears; Effective: vision improves more than 2 row, the hemorrhage basic absorption of macula area, fluoroscopic visualization display new vessels exists, the comparatively front basic absorption in choroid background fluorescence blocked area; Effective: it is capable that vision improves 0-1, macula area bleeding sites absorbs, the visible new vessels of fluoroscopic visualization, and choroid background fluorescence blocked area comparatively forward part absorbs; Invalid: vision does not improve or declines on the contrary, macula area absorption of hemorrhage slowly or not absorbs, or Repeated Hemorrhage, and the visible new vessels of fluoroscopic visualization, fluorescence blocked area scope even expands without reducing.
9, therapeutic effect:
In clinical observation process, treatment group and matched group all complete clinical observation.Treat efficacy result after two weeks as shown in table 1 below:
Efficacy result after two weeks treated by table 1.
| Group | Cure | Effective | Effectively | Invalid | Total effective rate |
| Treatment group | 9 | 13 | 8 | 5 | 85.7％ |
| Matched group | 5 | 9 | 10 | 9 | 72.7％ |
Treating treatment group total effective rate after two weeks is 85.7%, and matched group total effective rate is 72.7%, P > 0.05, both no significant differences, but treatment group is better than matched group.
Treatment surrounding after two groups of therapeutic outcomes be compared as follows shown in table table 2:
Two groups of therapeutic outcomes after surrounding treated by table 2.
| Group | Cure | Effective | Effectively | Invalid | Total effective rate |
| Treatment group | 12 | 14 | 7 | 2 | 94.3％ |
| Matched group | 8 | 10 | 9 | 6 | 81.8％ |
After treatment surrounding, treatment group total effective rate is 94.3%, and matched group total effective rate is 81.8%, P < 0.05, prove that two kinds of Therapeutic Method have significant difference, and the curative effect for the treatment of group is better than matched group.In treatment group therapeutic process, vital sign steadily and without serious adverse reactions such as allergy, show that the clinical application of we is safely and effectively, is worth studying and applying further.
Claims (6)
1. treat a pharmaceutical composition for macular hemorrhage in high myopia, it is characterized in that, its raw material primarily of following weight portion obtains: Radix Ginseng 6-8 part, Fructus Lycii 10-12 part, Arillus Longan 10-12 part, Fructus Rubi 8-11 part, Pollen Typhae 6-8 part, Flos Granati 10-12 part, Rhizoma Coptidis 6-8 part, Ramulus Cinnamomi 7-9 part, Colla Corii Asini 5-7 part, Radix Notoginseng 8-12 part, Fructus Ligustri Lucidi 10-12 part.
2. pharmaceutical composition as claimed in claim 1, it is characterized in that, described pharmaceutical composition also comprises Semen Plantaginis 8-10 part and Caulis Trachelospermi 8-12 part.
3. pharmaceutical composition as claimed in claim 2, is characterized in that, its raw material primarily of following weight portion obtains: Radix Ginseng 7 parts, Fructus Lycii 11 parts, Arillus Longan 11 parts, Fructus Rubi 9 parts, Pollen Typhae 7 parts, Flos Granati 11 parts, Rhizoma Coptidis 7 parts, Ramulus Cinnamomi 8 parts, 6 parts, Colla Corii Asini, Radix Notoginseng 10 parts, Fructus Ligustri Lucidi 11 parts, Semen Plantaginis 9 parts, Caulis Trachelospermi 10 parts.
4. the pharmaceutical composition as described in as arbitrary in claim 1-3, it is characterized in that, described pharmaceutical composition is oral formulations.
5. pharmaceutical composition as claimed in claim 4, it is characterized in that, described oral formulations is tablet or capsule.
6. the pharmaceutical composition as described in as arbitrary in claim 1-3 hinders the purposes in network type macular hemorrhage in high myopia medicine in preparation treatment asthenic fire.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510070345.9A CN104587094A (en) | 2015-02-11 | 2015-02-11 | Pharmaceutical composition for treating macular hemorrhage in high myopia and application of pharmaceutical composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510070345.9A CN104587094A (en) | 2015-02-11 | 2015-02-11 | Pharmaceutical composition for treating macular hemorrhage in high myopia and application of pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104587094A true CN104587094A (en) | 2015-05-06 |
Family
ID=53113365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510070345.9A Pending CN104587094A (en) | 2015-02-11 | 2015-02-11 | Pharmaceutical composition for treating macular hemorrhage in high myopia and application of pharmaceutical composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104587094A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108837042A (en) * | 2018-09-10 | 2018-11-20 | 云南东煌生物科技有限公司 | A kind of Chinese materia medica preparation for treating eyes illness |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1772261A (en) * | 2005-11-11 | 2006-05-17 | 何伟 | Oral medicine for treafing eye inflammation, lession and hemorrhage and its prepn |
| CN103070992A (en) * | 2013-01-11 | 2013-05-01 | 管学刚 | Medicine for treating high myopia macular hemorrhages |
| CN103071046A (en) * | 2013-01-22 | 2013-05-01 | 管丽芳 | Medicine paste for treating high myopia macular hemorrhage |
-
2015
- 2015-02-11 CN CN201510070345.9A patent/CN104587094A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1772261A (en) * | 2005-11-11 | 2006-05-17 | 何伟 | Oral medicine for treafing eye inflammation, lession and hemorrhage and its prepn |
| CN103070992A (en) * | 2013-01-11 | 2013-05-01 | 管学刚 | Medicine for treating high myopia macular hemorrhages |
| CN103071046A (en) * | 2013-01-22 | 2013-05-01 | 管丽芳 | Medicine paste for treating high myopia macular hemorrhage |
Non-Patent Citations (1)
| Title |
|---|
| 许静等: ""任征论治高度近视性黄斑出血经验"", 《浙江中医杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108837042A (en) * | 2018-09-10 | 2018-11-20 | 云南东煌生物科技有限公司 | A kind of Chinese materia medica preparation for treating eyes illness |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103656290B (en) | Medicine for treating optic atrophy and preparation method of medicine | |
| CN103191368A (en) | Medicine for treating leucoderma and preparation method thereof | |
| CN102579840B (en) | Chinese medicinal composition with effects of reducing intraocular pressure and protecting optic nerves and preparation method thereof | |
| CN103638326B (en) | Medicament for treating cataract and preparation method of medicament | |
| CN104524071A (en) | Pharmaceutical composition for treating primary renal disease and application thereof | |
| CN101703625B (en) | Oral Chinese medicinal composition for treating glaucoma | |
| CN104587094A (en) | Pharmaceutical composition for treating macular hemorrhage in high myopia and application of pharmaceutical composition | |
| CN102961712A (en) | Pure traditional Chinese medicine compound preparation for treating myoma of uterus and preparation method thereof | |
| CN104524524B (en) | Medicine treating osteoporosis and preparing method | |
| CN103301431A (en) | Traditional Chinese medicinal preparation for treating glaucoma and preparation method thereof | |
| CN106727993A (en) | A kind of medicine for treating gynaecology's fertility | |
| CN105213887A (en) | One is used for the treatment of glaucomatous Chinese medicine composition | |
| CN104383152A (en) | Traditional Chinese medicine preparation for treating glaucoma and preparation method of traditional Chinese medicine preparation | |
| CN104306546A (en) | A traditional Chinese medicine composition used for treating optic atrophy, and decoctions, pills and powder of the composition | |
| CN104056224A (en) | Medicine for treating habitual abortion and preparation method thereof | |
| CN104324139B (en) | A kind of pharmaceutical composition treating xerophthalmia | |
| CN103550455B (en) | Traditional Chinese medicine for treating glaucoma | |
| CN103610797B (en) | Traditional Chinese medicine composition for treating keratoconjunctivitis due to congestion and excess of dampness-heat | |
| CN103432361B (en) | Chinese medicinal plaster for treating cervical erosion | |
| CN101612288A (en) | The Chinese medicine that treatment of diabetic retinopathy becomes | |
| CN104587139A (en) | Pharmaceutical composition for treating juvenile myopia and application of pharmaceutical composition | |
| CN104800405A (en) | Traditional Chinese medicine composition for treating normal intraocular pressure glaucoma | |
| CN105125990A (en) | Traditional Chinese medicine gel for promoting wound healing in lateral perineotomy | |
| CN104771732A (en) | Traditional Chinese medicine composition for treating allergic asthma | |
| CN103611144B (en) | Medicine for treating uterine prolapse and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150506 |
|
| RJ01 | Rejection of invention patent application after publication |